Proteomics International Laboratories Ltd. ( (AU:PIQ) ) has issued an announcement.
Proteomics International Laboratories Ltd reported a 29% increase in revenue from operating and other activities for the half-year ending December 31, 2024, reaching $962,000. Despite the revenue growth, the company experienced an 18% increase in net loss, amounting to $4.503 million. The financial report highlights a reduction in net cash outflow from operating and investing activities, while cash and cash equivalents stood at $5.325 million by the end of the period. These financial results indicate ongoing challenges in achieving profitability, but also reflect improved cash management and operational efficiency.
More about Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd, based in Perth, Western Australia, operates as a medical technology company specializing in precision diagnostics and bio-analytical services. The company focuses on proteomics, which involves the large-scale study of proteins’ structure and function, aiming to enhance disease treatment through innovative diagnostic tools.
YTD Price Performance: -26.88%
Average Trading Volume: 149,685
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$76.64M
See more data about PIQ stock on TipRanks’ Stock Analysis page.